any one watshing this stock?, page-2

re: elie2000/any one watshing this stock? G'day Elie,
Here's the March 4th, '03 Report, as sent out to Share Holders.
~"The trial is expected to be completed in 12 to 18 months"~
Time is the factor here, still a long way to go although this is a further step in the right direction.
I've been holding MTR for quite a while and, if the tests on humans prove to be successful then patience will be rewarded.....but, it's a long time coming.
You didn't mention if you were entering on the premise of a quick trade or contemplating the "long haul".
Anyhow, whatever your plan of attack is....good luck if you decide to buy.
Cheers,
Carl.

PHASE II CLINICAL TRIAL TO COMMENCE
* Milestone achieved
* Meditech’s HyFIVE™ & HyCAMP™ to be trialed on
colorectal cancer
* Outcomes ­ prolonged survival / reduction in side
effects
* Trials to be conducted through the CDCT in Melbourne,
Australia
________________________________________________________________


Meditech Research Limited (“MEDITECH”) (ASX: MTR) today announced that the Company has been granted ethics committee approval to commence a Phase II human clinical trial that will involve the use of two anticancer drugs, HyFIVE™ and HyCAMP™ for the treatment of colorectal (large bowel) cancer. These drugs are formulations of Meditech’s patented HyACT™ technology administered as an intravenous solution incorporating the existing widely used anticancer drugs 5-Fluorouracil and Irinotecan.


Colorectal cancer is one of the most prevalent and lethal forms of cancer in the western world. Its incidence is growing as a consequence of many factors including diet, environment and the increased elderly population most prone to colorectal cancer.


The aim of this Phase II Trial is to demonstrate that the HyFIVE™ and HyCAMP™ formulations are not only effective in killing colorectal cancer cells in humans, but provide improved patient tolerability, thereby reducing or eliminating the requirement for patients to be prematurely withdrawn from treatment due to toxic side effects of the drugs. The trial will be conducted by the highly regarded Centre for the Development of Cancer Therapeutics at the Royal Melbourne Hospital. The trial is expected to be completed in 12 to 18 months. The initial component of the trial will be evaluation of the pharmacokinetics of HyCAMPTM in a small number of patients prior to combination with HyFIVETM.


Meditech believes that successful outcomes from this trial will place the Company in an ideal position to secure valuable commercial agreements with major multinational pharmaceutical companies who either currently produce and market 5-Fluorouracil and Irinotecan or seek to establish new and improved anticancer products.


Shareholders will be kept informed of the progress of the trials as information becomes available.


FOR FURTHER INFORMATION, CONTACT:

Dr Tracey Brown Prof Richard Fox,
Director of Operations Director
Phone (03) 9905 3760 Phone (03) 9342 7695



Chris Carter
Chief Executive Officer
Phone (03) 9296 2026
Mobile 0412 958 262



For more information on Meditech visit the Company website ­ www.mrl.com.au